HPV vaccination of immunocompromised hosts

It is well-established that immunocompromised people are at increased risk of HPV-related disease compared with those who are immunocompetent. Prophylactic HPV sub-unit vaccines are safe and immunogenic in immunocompromised people and it is strongly recommended that vaccination occur according to na...

Descripción completa

Detalles Bibliográficos
Autores principales: Garland, S.M., Brotherton, J.M.L., Moscicki, A.B., Kaufmann, A.M., Stanley, M., Bhatla, N., Sankaranarayanan, R., de Sanjosé, S., Palefsky, J.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5883202/
https://www.ncbi.nlm.nih.gov/pubmed/29179867
http://dx.doi.org/10.1016/j.pvr.2017.06.002
_version_ 1783311601057660928
author Garland, S.M.
Brotherton, J.M.L.
Moscicki, A.B.
Kaufmann, A.M.
Stanley, M.
Bhatla, N.
Sankaranarayanan, R.
de Sanjosé, S.
Palefsky, J.M.
author_facet Garland, S.M.
Brotherton, J.M.L.
Moscicki, A.B.
Kaufmann, A.M.
Stanley, M.
Bhatla, N.
Sankaranarayanan, R.
de Sanjosé, S.
Palefsky, J.M.
author_sort Garland, S.M.
collection PubMed
description It is well-established that immunocompromised people are at increased risk of HPV-related disease compared with those who are immunocompetent. Prophylactic HPV sub-unit vaccines are safe and immunogenic in immunocompromised people and it is strongly recommended that vaccination occur according to national guidelines. When delivered to immunocompromised populations, HPV vaccines should be given as a 3-dose regimen.
format Online
Article
Text
id pubmed-5883202
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-58832022018-04-11 HPV vaccination of immunocompromised hosts Garland, S.M. Brotherton, J.M.L. Moscicki, A.B. Kaufmann, A.M. Stanley, M. Bhatla, N. Sankaranarayanan, R. de Sanjosé, S. Palefsky, J.M. Papillomavirus Res Article It is well-established that immunocompromised people are at increased risk of HPV-related disease compared with those who are immunocompetent. Prophylactic HPV sub-unit vaccines are safe and immunogenic in immunocompromised people and it is strongly recommended that vaccination occur according to national guidelines. When delivered to immunocompromised populations, HPV vaccines should be given as a 3-dose regimen. Elsevier 2017-06-03 /pmc/articles/PMC5883202/ /pubmed/29179867 http://dx.doi.org/10.1016/j.pvr.2017.06.002 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Garland, S.M.
Brotherton, J.M.L.
Moscicki, A.B.
Kaufmann, A.M.
Stanley, M.
Bhatla, N.
Sankaranarayanan, R.
de Sanjosé, S.
Palefsky, J.M.
HPV vaccination of immunocompromised hosts
title HPV vaccination of immunocompromised hosts
title_full HPV vaccination of immunocompromised hosts
title_fullStr HPV vaccination of immunocompromised hosts
title_full_unstemmed HPV vaccination of immunocompromised hosts
title_short HPV vaccination of immunocompromised hosts
title_sort hpv vaccination of immunocompromised hosts
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5883202/
https://www.ncbi.nlm.nih.gov/pubmed/29179867
http://dx.doi.org/10.1016/j.pvr.2017.06.002
work_keys_str_mv AT garlandsm hpvvaccinationofimmunocompromisedhosts
AT brothertonjml hpvvaccinationofimmunocompromisedhosts
AT moscickiab hpvvaccinationofimmunocompromisedhosts
AT kaufmannam hpvvaccinationofimmunocompromisedhosts
AT stanleym hpvvaccinationofimmunocompromisedhosts
AT bhatlan hpvvaccinationofimmunocompromisedhosts
AT sankaranarayananr hpvvaccinationofimmunocompromisedhosts
AT desanjoses hpvvaccinationofimmunocompromisedhosts
AT palefskyjm hpvvaccinationofimmunocompromisedhosts
AT hpvvaccinationofimmunocompromisedhosts

Ejemplares similares